Founder/CEO at Lumen Bio. I'm a quasi-outsider to the biopharma industry, interested in the economics of drug development.

Joined August 2009
36 Photos and videos
Brian Finrow retweeted
Replying to @AndrewE_Dunn
What’s driving these changes? You can outsource early stage science to China for 1/5 of the cost at 2x the speed.
5
4
30
6,991
Writing again here with my friend Kevin Klowden (@MilkenInstitute) in @dddmag:  the twin challenges of AI drug design and China's advent as a drug-development superpower are causing interesting changes in the U.S. biopharma innovation ecosystem has a complex ecology. Lots of subtle implications for patent defensibility, and therefore biotech business models. We discuss 3 examples of how some innovative companies are responding (including Seattle's @VariantBio and @LumenBio, naturally).
1
1
83
Brian Finrow retweeted
The largest and sharpest image ever taken of the Andromeda galaxy — otherwise known as M31. It is the biggest Hubble image ever released and shows over 100 million stars, thousands of star clusters in a section of the galaxy’s disc stretching across over 40 000 light-years.
141
899
5,060
166,087
Pitch-perfect language here from the House Appropriations Committee for anyone interested in restoring U.S. competitiveness in early-stage drug development. They've clearly got someone with deep expertise helping out. @RuxandraTeslo & @joshcmorrison? 😉
2
3
26
4,965

26 Dec 2025
If we lose to China in biotech, the proximal, nucleating cause, will be the failure of our regulatory apparatus to respond with a more decentralized, IRB and Investigator-driven, fast path to human proof of concept, without massive manufacturing burden. Fix it.
126
Brian Finrow retweeted
This is a hilariously disappointing result: 15% of placebo GLP-1 patients seemingly realized they weren't getting the real stuff and so they went out and got it on their own. They're undermining the trials because they want to lose weight!
🔔Survodutide SYNCHRONIZE-1 full paper is out for Boehringer-Ingelheim’s GLP-1/Glucagon study for weight loss. ▪️13% loss on 6mg (treatment regimen estimand) ▪️Huge treatment discontinuations due to AEs: 20% ▪️Nausea 65%, Vomiting 45% ▪️Placebo was killer. 5.4% WL. Wow. ▪️60% women ▪️Very global study
62
165
3,501
364,206
Brian Finrow retweeted
'The surge in new US business formation is being fueled by AI and large language models, which are dramatically reducing the cost and complexity of launching a company' @apolloglobal
6
26
88
18,824
Brian Finrow retweeted
Replying to @JTLonsdale
Something that is underappreciated is China has 4x the population and Tier 1 cities are 30 million people, so easier to recruit and finish studies. However, their Phase 1 process is more like Australia and have more silent approval; if you don’t hear from us, proceed. Australia is fast for Phase 1 and they have more silent approval, but they are just doing safety and know the pivotal trials will primarily be done in US & other countries. FDA tends to view Phase 1 as precedent for the entire drug program all the way through Phase 3, so they want everything to be in order from the start like CMC. I would say Australia doesn’t really care about CMC b/c that will be covered by US during trials and scale up. For Phase 1 just need smaller batch manufacturing, do not necessarily need to be set up with standards for Phase 2 or 3 larger trials, but it makes thing smoother.
2
19
1,344
Brian Finrow retweeted
May 29
bleak that the primary people who are worried about chinese biotech are people who actually work in the field, and everyone telling them to chill out are either VC’s or journalists
18
34
303
28,310
Brian Finrow retweeted
We’re deeply committed to reforming our IND/Phase 1 process. We must retain our position as the world leader in biotech.
74
38
352
46,334
Brian Finrow retweeted
A real downside of the rise of LLMs is that we now have to sit through Cloudflare verification pages all the time.
49
65
3,618
63,968
Brian Finrow retweeted
1/ For nearly 350 years, science has communicated itself through one object: the paper. A linear narrative, frozen as a PDF, written for a human reader. We've come to treat that format as the medium of science itself. It doesn't have to be. It's a historical artifact. 🧵
28
136
1,067
141,327
Brian Finrow retweeted
There's a common misconception that Brutalist buildings were unpainted, but thanks to microscopic analysis of the exteriors we can now recreate what they looked like in their prime.
443
3,329
39,368
7,428,104
Brian Finrow retweeted
Wealth permits a morality to exist that would be incomprehensible to our ancestors. E.g. Germany yesterday finally captured the stranded whale whose story had gripped the nation, and is now escorting him via barge back to the deeper Atlantic. An enormous, multiday operation.
111
546
8,804
365,762
Brian Finrow retweeted
The dream of China surpassing the U.S. as the world’s largest economy is fading. In 2021, China’s GDP was about 78% of the U.S.; by 2024, that share had fallen to roughly 64%, back to around 2017 levels, with the gap between the two economies doubling in just a few years.
539
1,359
7,438
1,056,902
Brian Finrow retweeted
There is more high tech in Israel than in Italy w x 6 the population because rich Israelis invest in the risky projects of young Israelis while rich Italians more prudently demand safer investments. The result of all that prudence is a terrible stagnation that pols ignore
84
178
1,404
68,029